Patents Assigned to Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana
  • Patent number: 11915420
    Abstract: A method is disclosed for obtaining an image biomarker that quantifies the quality of the trabecular structure of bones. The method includes: retrieving high-resolution CT (Computed Tomography) and/or MRI (Magnetic Resonance Imaging) trabecular images from an image database; pre-processing and post-processing the high-resolution CT and/or MRI trabecular images and obtaining the unique image biomarker “QTS”. Pre-processing may include: calculating the region of interest “ROI”; calculating the bone fraction map; eliminating the partial volume effect; and, binarizing. Post-processing may include: skeletonisation and extraction of morphological and structural characteristics. Lastly, the unique image biomarker “QTS” is defined as: QTS=0.7137*Comp1+0.2863*Comp2.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 27, 2024
    Assignees: Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana, QUIBIM, S.L., UNIVERSIDAD DE ZARAGOZA
    Inventors: Angel Alberich Bayarri, Fabio García Castro, Amadeo Ten Esteve, Luis Martí Bonmatí, María Ángeles Pérez Ansón
  • Publication number: 20220081725
    Abstract: The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 17, 2022
    Applicants: Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana, Maastricht University
    Inventors: David Hervàs Marìn, Ana Santaballa Beltràn, Carmen Salvador Coloma, Rubèn Carrero Garcìa, Rafael Sanchez Sanchez, Akaitz Dorronsoro Gonzàlez, Imelda Ontoria Oviedo, Sandra Tejedor Gascòn, Estaban Peiró Molina, Amparo Hernàndiz Martinez, Hernán González-King, María Ciria Calduch, Delia Castellano Izquierdo, Joaquín Panadero Romero, Jose Anastasio Montero Argudo, Pilar Sepúlveda Sanchis, Nahuel A. García, Florian Caiment, Jos Kleinjans, Stephane Heymans, Jort Merken